Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2005 2
2006 5
2007 3
2008 12
2009 9
2010 17
2011 19
2012 18
2013 19
2014 16
2015 18
2016 9
2017 7
2018 5
2019 11
2020 8
2021 1
2022 2
2023 4
2024 2
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

158 results

Results by year

Filters applied: . Clear all
Page 1
Compliance and clinical benefit of deferasirox granule and dispersible tablet formulation in pediatric patients with transfusional iron overload: in a randomized, open-label, multicenter, phase II study.
Taher AT, Wali Y, Cruz MC, Charoenkwan P, Aydinok Y, Werner O, Govindaraju S, Romen F, Viprakasit V. Taher AT, et al. Haematologica. 2024 May 1;109(5):1413-1425. doi: 10.3324/haematol.2023.283133. Haematologica. 2024. PMID: 37855069 Free PMC article. Clinical Trial.
Identifier: NCT02435212), a randomized, open-label, multicenter, phase II study evaluated the compliance, clinical benefits, and safety of deferasirox granules and dispersible tablets (DT) in pediatric patients with iron overload. ...In iron chelation therapy-naive patient …
Identifier: NCT02435212), a randomized, open-label, multicenter, phase II study evaluated the compliance, clinical benefits, and safety of …
Cardiac effects of deferasirox in transfusion-dependent patients with myelodysplastic syndromes: TELESTO study.
Sarocchi M, Li J, Li X, Wu D, Montaño Figueroa E, Rodriguez MG, Hou M, Finelli C, Shi HX, Xiao Z, Oliva EN, Gercheva Kyuchukova L, Drummond M, Symeonidis A, Velazquez EJ, Rivoli G, Izquierdo M, Kolekar Y, Spallarossa P, Angelucci E. Sarocchi M, et al. Br J Haematol. 2024 May;204(5):2049-2056. doi: 10.1111/bjh.19316. Epub 2024 Feb 11. Br J Haematol. 2024. PMID: 38343073 Clinical Trial.
Patients receiving deferasirox experienced a significant decrease in the composite risk of hospitalisation for congestive heart failure (CHF) or worsening of cardiac function (HR = 0.23; 95% CI: 0.05, 0.99; nominal p = 0.0322) versus placebo. ...These results support the e …
Patients receiving deferasirox experienced a significant decrease in the composite risk of hospitalisation for congestive heart failu …
Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial.
Maggio A, Kattamis A, Felisi M, Reggiardo G, El-Beshlawy A, Bejaoui M, Sherief L, Christou S, Cosmi C, Della Pasqua O, Del Vecchio GC, Filosa A, Cuccia L, Hassab H, Kreka M, Origa R, Putti MC, Spino M, Telfer P, Tempesta B, Vitrano A, Tsang YC, Zaka A, Tricta F, Bonifazi D, Ceci A. Maggio A, et al. Lancet Haematol. 2020 Jun;7(6):e469-e478. doi: 10.1016/S2352-3026(20)30100-9. Lancet Haematol. 2020. PMID: 32470438 Clinical Trial.
To our knowledge, there are no randomised clinical trials comparing deferiprone, a less expensive iron chelator, with deferasirox in paediatric patients. We aimed to show the non-inferiority of deferiprone versus deferasirox. ...Median follow-up was 379 days (IQR 29 …
To our knowledge, there are no randomised clinical trials comparing deferiprone, a less expensive iron chelator, with deferasirox in …
Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial).
Angelucci E, Santini V, Di Tucci AA, Quaresmini G, Finelli C, Volpe A, Quarta G, Rivellini F, Sanpaolo G, Cilloni D, Salvi F, Caocci G, Molteni A, Vallisa D, Voso MT, Fenu S, Borin L, Latte G, Alimena G, Storti S, Piciocchi A, Fazi P, Vignetti M, Tura S. Angelucci E, et al. Eur J Haematol. 2014 Jun;92(6):527-36. doi: 10.1111/ejh.12300. Epub 2014 Apr 10. Eur J Haematol. 2014. PMID: 24580147 Clinical Trial.
The effects of deferasirox therapy on hematological response and disease progression were also examined. ...Of 84 patients who discontinued deferasirox therapy, 22 died during the trial, and 28 withdrew due to an adverse event (AE). ...
The effects of deferasirox therapy on hematological response and disease progression were also examined. ...Of 84 patients who discon …
Long-term sequential deferiprone and deferasirox therapy in transfusion-dependent thalassaemia patients: a prospective clinical trial.
Vitrano A, Ruffo GB, Pepe A, D'Ascola DG, Caruso V, Filosa A, Masera N, Pitrolo L, Rigano P, Cuccia L, Giangreco A, Di Maggio R, Maggio A. Vitrano A, et al. Br J Haematol. 2019 Sep;186(6):e209-e211. doi: 10.1111/bjh.16101. Epub 2019 Jul 25. Br J Haematol. 2019. PMID: 31344255 Free article. Clinical Trial. No abstract available.
Comparative effectiveness of adding omega-3 and Manuka honey combination to conventional therapy in preventing and treating oxidative stress in pediatric β-thalassemia major - a randomized clinical trial.
Gamaleldin M, Abraham I, Meabed M, Elberry A, Abdelhalim S, Waggas D, Hussein R. Gamaleldin M, et al. Eur Rev Med Pharmacol Sci. 2023 Jul;27(13):6058-6070. doi: 10.26355/eurrev_202307_32960. Eur Rev Med Pharmacol Sci. 2023. PMID: 37458648 Free article. Clinical Trial.
The present study examined the effectiveness of omega-3 and Manuka honey combination or Manuka honey alone to the conventional therapy (deferasirox, blood transfusion, and L-carnitine) used for preventing and managing oxidative stress or iron overload-induced oxidative str …
The present study examined the effectiveness of omega-3 and Manuka honey combination or Manuka honey alone to the conventional therapy (d …
A 1-year randomized trial of deferasirox alone versus deferasirox and deferoxamine combination for the treatment of iron overload in thalassemia major.
Eghbali A, Shokri P, Afzal RR, Bagheri B. Eghbali A, et al. Transfus Apher Sci. 2019 Aug;58(4):429-433. doi: 10.1016/j.transci.2019.03.021. Epub 2019 Apr 24. Transfus Apher Sci. 2019. PMID: 31229401 Clinical Trial.
Our purpose was to compare effects of deferasirox versus deferasirox and deferoxamine in patients with thalassemia major. METHODS: This randomized and double blind trial was performed on 62 patients. Patients were assigned 1:1 to oral 30 mg/kg deferasirox dai …
Our purpose was to compare effects of deferasirox versus deferasirox and deferoxamine in patients with thalassemia major. METH …
Long-term safety and efficacy of deferasirox in patients with myelodysplastic syndrome, aplastic anemia and other rare anemia in Taiwan.
Ko BS, Chang MC, Chiou TJ, Chang TK, Chen YC, Lin SF, Chang CS, Lu YC, Yeh SP, Chen TY, Hwang WS. Ko BS, et al. Hematology. 2019 Dec;24(1):247-254. doi: 10.1080/16078454.2018.1557860. Hematology. 2019. PMID: 30558522 Free article. Clinical Trial.
In the overall patient population, deferasirox effectively decreased serum ferritin levels at 1 year (P = 0.0154) and 3 years (P = 0.0424) from the baseline. Upon the use of deferasirox, 32.9% patients showed erythroid response and 16.7% patients had platelet respon …
In the overall patient population, deferasirox effectively decreased serum ferritin levels at 1 year (P = 0.0154) and 3 years (P = 0. …
Efficacy of Deferasirox for the treatment of iron overload in Chinese thalassaemia major patients: results from a prospective, open-label, multicentre clinical trial.
Lai YR, Liu RR, Li CF, Huang SL, Li Q, Habr D, Martin N, Shen ZX. Lai YR, et al. Transfus Med. 2013 Dec;23(6):389-96. doi: 10.1111/tme.12077. Epub 2013 Oct 23. Transfus Med. 2013. PMID: 24147622 Clinical Trial.
METHODS: Efficacy and safety of deferasirox were compared in Chinese (n = 117) and non-Chinese (n = 998) TM patients. Deferasirox was initiated at 20 mg kg(-1) day(-1), with titration increments of 5-10 mg kg(-1) day(-1), based on serum ferritin trends and safety pa …
METHODS: Efficacy and safety of deferasirox were compared in Chinese (n = 117) and non-Chinese (n = 998) TM patients. Deferasirox …
Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea.
Vichinsky E, Torres M, Minniti CP, Barrette S, Habr D, Zhang Y, Files B; study CICL670A2201 investigators. Vichinsky E, et al. Am J Hematol. 2013 Dec;88(12):1068-73. doi: 10.1002/ajh.23569. Epub 2013 Sep 19. Am J Hematol. 2013. PMID: 23946212 Free article. Clinical Trial.
We report a prospective, randomized, Phase II study of deferasirox and deferoxamine (DFO) in sickle cell disease patients with transfusional iron overload, with all patients continuing on deferasirox after 24 weeks, for up to 2 years. The primary objective was to ev …
We report a prospective, randomized, Phase II study of deferasirox and deferoxamine (DFO) in sickle cell disease patients with transf …
158 results